U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Meningioma

MedGen UID:
1728199
•Concept ID:
C5419975
•
Neoplastic Process

Definition

Meningioma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Meningioma

Professional guidelines

PubMed

Efficacy and safety of peptide receptor radionuclide therapy with [(177)Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.
Minczeles NS, Bos EM, de Leeuw RC, Kros JM, Konijnenberg MW, Bromberg JEC, de Herder WW, Dirven CMF, Hofland J, Brabander T
Eur J Nucl Med Mol Imaging 2023 Mar;50(4):1195-1204. Epub 2022 Dec 1 doi: 10.1007/s00259-022-06044-9. PMID: 36454268
Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data.
Jensen LR, Maier AD, Lomstein A, Graillon T, Hrachova M, Bota D, Ruiz-Patiño A, Arrieta O, Cardona AF, Rudà R, Furtner J, Roeckle U, Clement P, Preusser M, Scheie D, Broholm H, Kristensen BW, Skjøth-Rasmussen J, Ziebell M, Munch TN, Fugleholm K, Walter MA, Mathiesen T, Mirian C
Neurosurg Rev 2022 Oct;45(5):3067-3081. Epub 2022 Aug 19 doi: 10.1007/s10143-022-01849-6. PMID: 35984552
Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis.
Mirian C, Duun-Henriksen AK, Maier A, Pedersen MM, Jensen LR, Bashir A, Graillon T, Hrachova M, Bota D, van Essen M, Spanjol P, Kreis C, Law I, Broholm H, Poulsgaard L, Fugleholm K, Ziebell M, Munch T, Walter MA, Mathiesen T
J Nucl Med 2021 Apr;62(4):507-513. Epub 2020 Aug 28 doi: 10.2967/jnumed.120.249607. PMID: 32859705

Recent clinical studies

Etiology

Efficacy and safety of peptide receptor radionuclide therapy with [(177)Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.
Minczeles NS, Bos EM, de Leeuw RC, Kros JM, Konijnenberg MW, Bromberg JEC, de Herder WW, Dirven CMF, Hofland J, Brabander T
Eur J Nucl Med Mol Imaging 2023 Mar;50(4):1195-1204. Epub 2022 Dec 1 doi: 10.1007/s00259-022-06044-9. PMID: 36454268
Somatostatin Receptor Theranostics for Refractory Meningiomas.
Salgues B, Graillon T, Horowitz T, Chinot O, Padovani L, Taïeb D, Guedj E
Curr Oncol 2022 Aug 4;29(8):5550-5565. doi: 10.3390/curroncol29080438. PMID: 36005176Free PMC Article
Multimodality Therapy of Patients with Refractory Meningiomas.
Ahmad H, Schiff D
Curr Treat Options Oncol 2019 May 9;20(6):50. doi: 10.1007/s11864-019-0648-z. PMID: 31073797
Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs.
Dasanu CA, Alvarez-Argote J, Limonadi FM, Codreanu I
Expert Opin Biol Ther 2019 Feb;19(2):99-104. Epub 2018 Dec 17 doi: 10.1080/14712598.2019.1559292. PMID: 30556741
Temozolomide for treatment-resistant recurrent meningioma.
Chamberlain MC, Tsao-Wei DD, Groshen S
Neurology 2004 Apr 13;62(7):1210-2. doi: 10.1212/01.wnl.0000118300.82017.f4. PMID: 15079029

Diagnosis

68Ga-DOTATOC PET in Extracranial Hepatic and Bone Metastasis of Atypical Refractory Meningioma: A Case Report.
Ghomari CF, Bender L, Lhermitte B, Noël G, Namer IJ, Bund C
Clin Nucl Med 2023 Feb 1;48(2):176-178. doi: 10.1097/RLU.0000000000004518. PMID: 36607366
Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas.
Jungwirth G, Yu T, Liu F, Cao J, Alaa Eddine M, Moustafa M, Abdollahi A, Warta R, Unterberg A, Herold-Mende C
Clin Cancer Res 2023 Jan 4;29(1):233-243. doi: 10.1158/1078-0432.CCR-22-2085. PMID: 36282277
Multimodality Therapy of Patients with Refractory Meningiomas.
Ahmad H, Schiff D
Curr Treat Options Oncol 2019 May 9;20(6):50. doi: 10.1007/s11864-019-0648-z. PMID: 31073797
Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas.
Peyre M, Zanello M, Mokhtari K, Boch AL, Capelle L, Carpentier A, Clemenceau S, Karachi C, Navarro S, Nouet A, Reina V, Valery CA, Sanson M, Cornu P, Kalamarides M
J Neurooncol 2015 May;123(1):151-60. Epub 2015 Apr 17 doi: 10.1007/s11060-015-1778-1. PMID: 25894596
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P
Neuro Oncol 2014 Jun;16(6):829-40. Epub 2014 Feb 4 doi: 10.1093/neuonc/not330. PMID: 24500419Free PMC Article

Therapy

Somatostatin Receptor Theranostics for Refractory Meningiomas.
Salgues B, Graillon T, Horowitz T, Chinot O, Padovani L, Taïeb D, Guedj E
Curr Oncol 2022 Aug 4;29(8):5550-5565. doi: 10.3390/curroncol29080438. PMID: 36005176Free PMC Article
Multimodality Therapy of Patients with Refractory Meningiomas.
Ahmad H, Schiff D
Curr Treat Options Oncol 2019 May 9;20(6):50. doi: 10.1007/s11864-019-0648-z. PMID: 31073797
Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs.
Dasanu CA, Alvarez-Argote J, Limonadi FM, Codreanu I
Expert Opin Biol Ther 2019 Feb;19(2):99-104. Epub 2018 Dec 17 doi: 10.1080/14712598.2019.1559292. PMID: 30556741
Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?
Dasanu CA, Samara Y, Codreanu I, Limonadi FM, Hamid O, Alvarez-Argote J
J Oncol Pharm Pract 2019 Apr;25(3):638-647. Epub 2018 Sep 26 doi: 10.1177/1078155218799850. PMID: 30253729
Temozolomide for treatment-resistant recurrent meningioma.
Chamberlain MC, Tsao-Wei DD, Groshen S
Neurology 2004 Apr 13;62(7):1210-2. doi: 10.1212/01.wnl.0000118300.82017.f4. PMID: 15079029

Prognosis

Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
Boursier C, Zaragori T, Bros M, Bordonne M, Melki S, Taillandier L, Blonski M, Roch V, Marie PY, Karcher G, Imbert L, Verger A
Eur Radiol 2023 Oct;33(10):7089-7098. Epub 2023 May 6 doi: 10.1007/s00330-023-09697-8. PMID: 37148355
Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data.
Jensen LR, Maier AD, Lomstein A, Graillon T, Hrachova M, Bota D, Ruiz-Patiño A, Arrieta O, Cardona AF, Rudà R, Furtner J, Roeckle U, Clement P, Preusser M, Scheie D, Broholm H, Kristensen BW, Skjøth-Rasmussen J, Ziebell M, Munch TN, Fugleholm K, Walter MA, Mathiesen T, Mirian C
Neurosurg Rev 2022 Oct;45(5):3067-3081. Epub 2022 Aug 19 doi: 10.1007/s10143-022-01849-6. PMID: 35984552
Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies.
Karsy M, Hoang N, Barth T, Burt L, Dunson W, Gillespie DL, Jensen RL
World Neurosurg 2016 Feb;86:210-9. Epub 2015 Sep 30 doi: 10.1016/j.wneu.2015.09.060. PMID: 26428319
Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas.
Peyre M, Zanello M, Mokhtari K, Boch AL, Capelle L, Carpentier A, Clemenceau S, Karachi C, Navarro S, Nouet A, Reina V, Valery CA, Sanson M, Cornu P, Kalamarides M
J Neurooncol 2015 May;123(1):151-60. Epub 2015 Apr 17 doi: 10.1007/s11060-015-1778-1. PMID: 25894596
Temozolomide for treatment-resistant recurrent meningioma.
Chamberlain MC, Tsao-Wei DD, Groshen S
Neurology 2004 Apr 13;62(7):1210-2. doi: 10.1212/01.wnl.0000118300.82017.f4. PMID: 15079029

Clinical prediction guides

Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
Eigler C, McDougall L, Bauman A, Bernhardt P, Hentschel M, Blackham KA, Nicolas G, Fani M, Wild D, Cordier D
J Nucl Med 2024 Apr 1;65(4):573-579. doi: 10.2967/jnumed.123.266817. PMID: 38423782
Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
Boursier C, Zaragori T, Bros M, Bordonne M, Melki S, Taillandier L, Blonski M, Roch V, Marie PY, Karcher G, Imbert L, Verger A
Eur Radiol 2023 Oct;33(10):7089-7098. Epub 2023 May 6 doi: 10.1007/s00330-023-09697-8. PMID: 37148355
Efficacy and safety of peptide receptor radionuclide therapy with [(177)Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.
Minczeles NS, Bos EM, de Leeuw RC, Kros JM, Konijnenberg MW, Bromberg JEC, de Herder WW, Dirven CMF, Hofland J, Brabander T
Eur J Nucl Med Mol Imaging 2023 Mar;50(4):1195-1204. Epub 2022 Dec 1 doi: 10.1007/s00259-022-06044-9. PMID: 36454268
Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas.
Jungwirth G, Yu T, Liu F, Cao J, Alaa Eddine M, Moustafa M, Abdollahi A, Warta R, Unterberg A, Herold-Mende C
Clin Cancer Res 2023 Jan 4;29(1):233-243. doi: 10.1158/1078-0432.CCR-22-2085. PMID: 36282277
Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data.
Jensen LR, Maier AD, Lomstein A, Graillon T, Hrachova M, Bota D, Ruiz-Patiño A, Arrieta O, Cardona AF, Rudà R, Furtner J, Roeckle U, Clement P, Preusser M, Scheie D, Broholm H, Kristensen BW, Skjøth-Rasmussen J, Ziebell M, Munch TN, Fugleholm K, Walter MA, Mathiesen T, Mirian C
Neurosurg Rev 2022 Oct;45(5):3067-3081. Epub 2022 Aug 19 doi: 10.1007/s10143-022-01849-6. PMID: 35984552

Recent systematic reviews

177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review.
Boursier C, Zaragori T, Imbert L, Verger A
Q J Nucl Med Mol Imaging 2024 Sep;68(3):217-225. Epub 2024 Jul 19 doi: 10.23736/S1824-4785.24.03571-4. PMID: 39026463
Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data.
Jensen LR, Maier AD, Lomstein A, Graillon T, Hrachova M, Bota D, Ruiz-Patiño A, Arrieta O, Cardona AF, Rudà R, Furtner J, Roeckle U, Clement P, Preusser M, Scheie D, Broholm H, Kristensen BW, Skjøth-Rasmussen J, Ziebell M, Munch TN, Fugleholm K, Walter MA, Mathiesen T, Mirian C
Neurosurg Rev 2022 Oct;45(5):3067-3081. Epub 2022 Aug 19 doi: 10.1007/s10143-022-01849-6. PMID: 35984552

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...